Clinical Trials Logo

Clinical Trial Summary

Sporotrichosis is a chronic granulomatous mycosis caused by sporothrix complex. The course of sporotrichosis is always prolonged and even life-threatening, the treatment of this disease in an important scientific problem to be solved. The investigators previously found the predominance of subtype M2 macrophage which play an anti-inflammatory role in the lesions of sporotrichosis, the predominance of M2 macrophage may be responsible for the persistence of sporotrichosis; the investigators also found that local hyperthermia is effective in the treatment of sporotrichosis and hyperthermia treatment can activate the CRAC calcium channel in macrophages which triggers pro-inflammatory type M1 polarization and subsequent killing of sporothrix, however, the mechanism still calls for further investigation. The investigators hypothesize that hyperthermia leads to the activation of CRAC channels resulting in profound Ca2+ influx and Ca2+ upregulates NLRP3 inflammasome expression through inducing Nrf2 activation, then NLRP3 overexpression triggers M1 polarization and subsequent killing of sporothrix. Furthermore, the activation of Nrf2 upregulates STIM1 expression which forms a positive feedback for M1 type polarization of macrophages and further subsequent killing of sporothrix. The purpose of this project is to identify the hypothesis that hyperthermia could treat sporotrichosis by promoting pro-inflammatory type M1 polarization in macrophages, the mechanism by which hyperthermia could treat sporotrichosis is local hyperthermia could led to STIM1/CRAC calcium channel activation mediated calcium ions/Nrf2/NLRP3 induced M1 macrophages polarization and subsequent killing of sporothrix. The hypothesis will be identified at the cellular level, at the animal model level and at the clinical specimens level. The investigators believe that the project will guide the application of hyperthermia in the treatment of sporotrichosis and provide a new basis of theory and practice after the investigators achieving these goals.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06300138
Study type Interventional
Source First Hospital of China Medical University
Contact Zhengxiu Li, Doctor
Phone 024-83282524
Email lizx_cmu@foxmail.com
Status Not yet recruiting
Phase N/A
Start date March 2024
Completion date December 2026

See also
  Status Clinical Trial Phase
Completed NCT00004808 - Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis Phase 2
Completed NCT00004811 - Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis Phase 1/Phase 2
Completed NCT00004938 - Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis Phase 2